Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
PUBT · 06/23 11:59
Share
Listen to the news
- Phathom Pharmaceuticals completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) in adult eosinophilic esophagitis.
- Topline results for the 12-week double-blind portion are expected in Q4 2026; results have not been presented yet.
- The placebo-controlled study is designed to assess whether vonoprazan can improve swallowing-related symptoms and disease activity versus placebo.
- A positive readout could support talks with the FDA on next development steps in EoE, including potential pediatric evaluation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230759PRIMZONEFULLFEED9750816) on June 23, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved